Lymphoma Clinical Trials in Reggio Emilia
20 recruitingReggio Emilia, Italy
Showing 1–20 of 20 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled112 locationsNCT06890884
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled52 locationsNCT05947851
Recruiting
Phase 2
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS56 enrolled24 locationsNCT06492837
Recruiting
Phase 1Phase 2
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Relapsed or Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS122 enrolled32 locationsNCT05300282
Recruiting
Not Applicable
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Classical Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Fondazione Italiana Linfomi - ETS552 enrolled40 locationsNCT05934084
Recruiting
Phase 2
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Diffuse Large B Cell Non-Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS47 enrolled20 locationsNCT06835530
Recruiting
Phase 2
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Refractory Mantle Cell LymphomaRelapsed Mantle Cell Lymphoma
Fondazione Italiana Linfomi - ETS49 enrolled21 locationsNCT05249959
Recruiting
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS1,500 enrolled61 locationsNCT06008691
Recruiting
Phase 2
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS28 enrolled18 locationsNCT04915248
Recruiting
Phase 3
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS190 enrolled48 locationsNCT05929222
Recruiting
Study on Plasmablastic Lymphoma Patients
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS200 enrolled23 locationsNCT06781359
Recruiting
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS130 enrolled21 locationsNCT06156774
Recruiting
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS56 enrolled14 locationsNCT06070961
Recruiting
Not Applicable
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
Advanced Solid TumorsOncologyLymphoma+3 more
Azienda USL Reggio Emilia - IRCCS75 enrolled1 locationNCT06795815
Recruiting
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Indolent B-Cell LymphomasIndolent B Cell Lymphoma
Azienda USL Reggio Emilia - IRCCS50 enrolled1 locationNCT06822829
Recruiting
Phase 3
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Diffuse Large B Cell LymphomaElderly Patients
Fondazione Italiana Linfomi - ETS430 enrolled49 locationsNCT04442412
Recruiting
Phase 3
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Mantle Cell Lymphoma
Prof. Dr. M. Dreyling (co-chairman)870 enrolled112 locationsNCT02858258